All of our existing therapies for Pulmonary Arterial Hypertension act by vasodilation or relaxing blood vessels. The current medications fall into one of three basic classes: 1. PDE5 inhibitor a. Sildenafil (Revatio/Viagra) b. Tadalafil (Adcirca/Cialiis) c. Riociguat (Adempas—not truly a PDE5inhibitor but similar action) 2. ERA a. Ambrisentan (Letairis) b. … [Read more...]
Liquidia: Exciting New Clinical Trial in Pulmonary Arterial Hypertension
Clinical trials are essential to improving the care of PAH patients. These clinical trials allow us to determine if new medicines are safe and effective. Clinical trials also allow us to make improvements to existing treatments. For example, we are eagerly awaiting the approval of the implanted pump for intravenous Remodulin. Another example of a company that is trying to … [Read more...]
Pulmonary Arterial Hypertension Research
FDA Approval Process for PAH Drugs The past decade has seen many new drugs approved to treat PAH. The development of a new drug is a long and expensive process. Candidate new drugs are identified and then enter the clinical research pathway. Before a medication is ever tested in humans, the medication is tested in a variety of laboratory settings and then in animal models. … [Read more...]
Pulmonary Arterial Hypertension Life Expectancy & Survival Rates
The treatment for Pulmonary Arterial Hypertension has come a long way since the mid 1990’s when Flolan was first approved. There has been an explosion of new medications that have dramatically altered how we treat patients. We no longer sequentially add therapies to most of our patients. Rather, we often start two or even three different therapies as part of an initial … [Read more...]
Help Arrives for Some PAH Patients Who Can’t Afford Their Medication
Thousands of Pulmonary Arterial Hypertension patients across America are now experiencing a crisis. They previously received support from Caring Voices Coalition. With the closing of Caring Voices, many of these patients have been unable to find foundation support, leaving them responsible for many thousands of dollars per month to receive their PAH medications. The PHA and … [Read more...]
